کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6170086 | 1251189 | 2013 | 9 صفحه PDF | دانلود رایگان |
PurposeTo describe usual care received by women with bony metastatic breast cancer (ICD-9: 174.xx and 198.5) treated in a United States specialty cancer hospital, an Electronic Medical Record (EMR)-based retrospective review identified 111 deceased female breast cancer patients â¥18 years of age treated with zoledronic acid (ZOL).ResultsBaseline symptoms included bone pain/fracture (58.6%), breathing difficulties (24.3%), or mental status changes (11.7%). ZOL was started at/after metastatic diagnosis for 75.7% of women (N = 84), with average administration of 15.9 months (median 11.3). Nearly 20% required reduced ZOL doses, most (54.5%) due to impaired renal function; 61.3% discontinued ZOL due to patient death/disease progression. Adverse events were reported in 10.8%, while 0.9% (N = 1) had a documented osteonecrosis of the jaw.ConclusionsInitiation of palliative care should be considered early in patients with a history of metastatic breast cancer who report bone pain or other skeletal-related events.
Journal: The Breast - Volume 22, Issue 4, August 2013, Pages 495-503